and left ventricular (LV) myocardium differ in their pathophysiological response to pressure-overload hypertrophy. In this report we use microarray and proteomic analyses to identify pathways modulated by LV-aortic banding (AOB) and RV-pulmonary artery banding (PAB) in the immature heart. Newborn New Zealand White rabbits underwent banding of the descending thoracic aorta [LV-AOB; n ϭ 6]. RV-PAB was achieved by banding the pulmonary artery (n ϭ 6). Controls (n ϭ 6 each) were sham-manipulated. After 4 (LV-AOB) and 6 (RV-PAB) wk recovery, the hearts were removed and matched RNA and proteins samples were isolated for microarray and proteomic analysis. Microarray and proteomic data demonstrate that in LV-AOB there is increased transcript expression levels for oxidative phosphorylation, mitochondria energy pathways, actin, ILK, hypoxia, calcium, and protein kinase-A signaling and increased protein expression levels of proteins for cellular macromolecular complex assembly and oxidative phosphorylation. In RV-PAB there is also an increased transcript expression levels for cardiac oxidative phosphorylation but increased protein expression levels for structural constituents of muscle, cardiac muscle tissue development, and calcium handling. These results identify divergent transcript and protein expression profiles in LV-AOB and RV-PAB and provide new insight into the biological basis of ventricular specific hypertrophy. The identification of these pathways should allow for the development of specific therapeutic interventions for targeted treatment and amelioration of LV-AOB and RV-PAB to ameliorate morbidity and mortality.
ultimately irreversible heart failure. Initially, the myocardium compensates to elevated pressure-loading by increasing wall thickness to normalize wall stress. These changes allow for maintenance of contractile function in left ventricular pressureoverload hypertrophy [LV-aortic banding (AOB)], whereas in right ventricular pressure-overload hypertrophy [RV-pulmonary artery banding (PAB)] these changes are less effective and progression to failure occurs more rapidly (2, 4, 15) .
Our previous studies using the rabbit model of LV-AOB and RV-PAB have demonstrated that disease progression involves both cellular and extracellular components of the myocardium. We have demonstrated that changes in cardiomyocyte viability, lack of adaptive capillary growth, fibrosis, and response to metabolic stress are differentially regulated in LV-AOB and RV-PAB (11, 13, 16, 20) . However, the mechanisms involved in the compensated phase of LV-AOB and RV-PAB have yet to be clearly elucidated. In this report we present microarray and proteomic analyses of the LV and RV during the compensated phase of progressive pressure-overload hypertrophy to identify differential transcript and protein expression levels and enriched pathways involved in LV-AOB and RV-PAB.
Our microarray and proteomic data demonstrate that in LV-AOB there is increased transcript expression levels for oxidative phosphorylation, mitochondria energy pathways, actin, ILK, hypoxia, calcium, and protein kinase-A signaling and increased protein expression levels of proteins for cellular macromolecular complex assembly and oxidative phosphorylation. In RV-PAB there is also increased transcript expression levels for cardiac oxidative phosphorylation but increased protein expression levels for structural constituents of muscle, cardiac muscle tissue development, and calcium handling. These findings demonstrate that modulation of mitochondrial function plays a dominant role in LV-AOB, whereas in RV-PAB both mitochondrial function and cardiac muscle tissue development are important. The identification of these pathways will allow for the development of specific therapeutic interventions for targeted treatment and amelioration of LV-AOB and RV-PAB.
METHODS
Ethics statement. All animals received humane care from the Animal Resources of Children's Hospital Boston and the investigation conforms to the Guide for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . The protocol was reviewed and approved by the Institutional Animal Care and Use Committee at Boston Children's Hospital.
Animal models. LV-and RV pressure-overload hypertrophy was created separately in 10-day-old New Zealand White rabbits (n ϭ 24). The rabbits were sedated with ketamine (40 -60 mg/kg im) and xylazine (2-5 mg/kg im). The surgical sites were shaved and prepped with Betadine and 70% isopropyl alcohol, each applied in triplicate and patted dry with sterile gauze pads, and the entire animal (except the surgical sites) draped with sterile towels. Bupivacaine (0.25%; Ͻ3 mg/kg) is infiltrated into the wound at the time of surgery. Anesthesia was maintained with 0.5-2% isoflurane (Forane; Abbott Laboratories, Chicago, IL) under spontaneous respiration, administered using a standard face mask.
For LV-AOB (n ϭ 6), a left thoracotomy in the 4th intercostal space was performed, the aorta was located, and a 2-0 silk suture was placed around the descending aorta just distal to the ligamentum arteriosum. Care was taken to make the banding snug without causing stenosis of the descending aorta as previously described (25) .
For RV-PAB (n ϭ 6), a left anterior-lateral thoracotomy in the 4th intercostal space was performed to allow access to the pulmonary artery. The pulmonary artery was isolated and banded using a lose 2-0 silk ligature to provide for constriction of the pulmonary artery by 25% of its diameter as previously described (16) .
Sham-operated control animals (LV and RV; n ϭ 6 each) received sedation, anesthesia, and thoracotomy as described above. The aorta (LV-sham-operated control) or pulmonary artery (RV-sham-operated control) was isolated and manipulated as described above, but no bands were placed.
The thoracotomy was closed in three layers with 4-0 chromic gut, and pleural air was evacuated over an angiocath. All suture knots were buried to minimize irritation felt by the animal. After completion of surgery, pain prophylaxis was administered (buprenorphine, 0.1 mg/ kg, and keterolac, 1 mg/kg im), anesthesia was ceased, and the rabbits were allowed to recover on a warming pad. Fig. 1 . Experimental flow chart. After recovery from aortic banding (AOB) or pulmonary artery banding (PAB), the rabbits were fully anesthetized and the hearts removed. Left ventricular (LV) and right ventricular (RV) free walls were dissected and used separately for RNA and protein isolation. A flow chart of transcriptomic and proteomic analysis is shown. Transcriptomic and proteomic analyses were performed on matched samples. Con, control.
The rabbits were returned to their mothers and allowed to grow in a normal manner. Progression of AOB and PAB was determined by weekly transthoracic echocardiography (Philips 7500) equipped with a S12 transducer. During these procedures, the animals remained unsedated to avoid the influences of anesthetics on the results.
The details on monitoring of progressive RV-and LV hypertrophy by echocardiography and analysis of tissue for cardiomyocyte and extracellular remodeling have been previously reported by our group in more detail (10, 11, 13, 16, 25) . After 4 wk (AOB) and 6 wk (PAB) recovery, the animals received an overdose of ketamine (100 mg/kg iv) and xylazine (10 mg/kg iv) with heparin (500 units/kg iv) and a thoracotomy was performed and the hearts were removed. The right and left atria and free wall of the LV and RV were removed and LV/RV and body weights were determined. The ratio of LV/RV weight (in gram) to body weight (in kilo) was compared with that of hearts from age-matched, nonhypertrophied, sham-operated control rabbits. Only the LV or RV free wall was used for matched sample RNA and protein isolation.
RNA and protein isolation. Total tissue RNA was isolated and quality and purity was assessed by spectrophotometric analysis and agarose gel electrophoresis as described previously (32) . Total tissue ventricular myocardial protein was isolated, and quality and purity was assessed by SDS-PAGE as described previously (23) .
Microarray and proteomic analysis. All microarray and proteomic analysis was performed using matched samples (Fig. 1 ).
Four replicates for each sample were analyzed for microarray and proteomics assays, respectively.
Microarray analysis. Microarray slide preparation/fabrication, print array, blocking, probe labeling and hybridization, scanning quality control, scanning and feature extraction, raw data analysis, and computational biology were performed at the Harvard FAS Center for Systems Biology.
Microarray analysis was performed as previously described using our nonredundant rabbit heart cDNA compendium consisting of 3,592 nonredundant cDNAs (mean insert size of 1.67 kb) (3, 23) . Putative identity was assigned only to cDNAs exhibiting matches to Homo sapiens or Oryctolagus cuniculus (rabbit) genes with Eϭ1e-25 (minimum P ϭ 10 -10) and nucleotide sequence identity Ͼ95%. This approach allows for ultimate usage in humans without the need for reisolation and sequence of the specific gene and the rapid verification of specific RNAs in humans using RT-PCR as sequence identity and thus oligomer sequence is readily available. All cDNA sequences have been submitted to GenBank and are available under accession numbers EC618425-EC626095 and dbEST40150263-40157933 and at https://sites.google.com/a/mccullylab.org/www/.
Microarray data analysis. The hybridized array images were analyzed with R and Bioconductor packages to extract normalized expression values for cDNA probes. The quality control analysis was performed using "arrayQualityMetrics" package in R to identify the outliers. The high quality arrays were further preprocessed and nor- malized using the Limma (Linear Models for Microarray Data) package from the Bioconductor project. The processed signal resulting from the scanner Genepix Feature Extraction software was read into Limma using the "read.maimages" function. The background corrected probe data were normalized using print-tip-loess and quantile normalization within and between arrays, respectively. The control and experimental groups for designed microarray experiments were compared by fitting a linear model for each gene and applying empirical Bayes smoothing to identify differentially expressed genes.
The genes with P value Ͻ0.01 were considered significantly differentially expressed. All microarray data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (7) and is accessible through GEO Series accession number GSE 30194 at http:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?accϭGSE30194.
Quantitative real-time RT-PCR. Quantitative RT-PCR (qRT-PCR) analysis was performed to validate changes in gene expression across experimental and treatment conditions by using an Eppendorf Realplex Mastercycler [and software package (Eppendorf North America, Westbury, NY)]. The iScript One-Step RT-PCR Kit with SYBR Green solution (Bio-Rad, Hercules, CA) was used for the qRT-PCR reactions according to manufacturer's instructions. In brief, 100 ng of total RNA and 600 nM of both forward and reverse primer were added to each reaction. Control, LV-AOB, and RV-PAB reactions were run for each primer set in triplicates. Control reactions without RT were also performed for each reaction.
Oligonucleotide primers (Table 5) were designed based on the laboratory's rabbit-nonredundant cDNA library sequence data using Primer3 (http://frodo.wi.mit.edu/) and were synthesized by Oligos ETC (Wilsonville, OR). Reaction kinetics were optimized for each primer set. Reverse transcription of RNA template occurred at 50°C for 10 min with inactivation at 95°C for 5 min. Amplification and detection occurred over 41 cycles (denaturing 95°C; 10 s, annealing 58 -63°C; 10 s, extension 72°C; 20 s, with plate read at 78°C). Melting curves were performed for each reaction at the conclusion of the cycling parameters from 60°to 95°C. Fold changes in gene expression were calculated by using the ⌬⌬ (⌬⌬CT) method (20) .
Validation and identification of qRT-PCR products. qRT-PCR products were verified by agarose gel and electrophoresis, and the products were purified using the QIAquick PCR purification kit (Qiagen, Valencia, CA) according to manufacturer's instructions. The purified products were sequenced by using the BigDye Terminator v1.1 and v3.1 Cycle Sequencing Kits (Applied Biosystems, Foster City, CA) using the 3130 xl Genetic Analyzer (Applied Biosystems, Foster City, CA) (2, 22) .
Proteomic analysis. High throughput profiling of protein samples was performed at the Genomics and Proteomics Center Core facility of the Beth Israel Deaconess Medical Center using the 8-plex iTRAQ (AB Sciex, Foster City, CA) labeling protocol and standard MudPIT methodology coupled with the 4800 MALDI TOF/TOF Plus instrument to perform the mass spectrometry as previously described (2).
Unsupervised and quality control analysis of proteomics data. The raw data were analyzed by the ProteinPilot v3.0 software (AB Sciex, Carlsbad, CA) using the new Paragon algorithm that enables rapid matching of MS/MS against the FASTA format SwissProt protein database. Each protein received a confidence score, with the overall confidence score ranging from 0% to 100% based on the total and best ion score. The proteins with confidence score greater than 90% and with at least one peptide of 95% identification confidence were used for further quality control and differential expression analysis. Each protein also achieved quantitative scores for each of the eight iTRAQ tags to calculate the relative expression levels. To compare results from one set of eight samples to the others, we compared all samples The quality control analysis was performed on the basis of relative expression values of different proteins to identify any outliers. The quality control analysis was performed using pair-wise correlation plots, boxplots, and principal component analysis. Each principal component is associated with an eigenvalue and is a measure of strength of each component, which corresponds to the amount of variability explained by the corresponding principal component.
Supervised analysis. To identify the differentially expressed proteins, the relative protein expression values were compared between groups (LV-AOB vs. control, RV-AOB vs. control, and LV-PAB vs. control, RV-PAB vs. control). Proteins were considered overexpressed in LV-AOB, RV-AOB or LV-PAB, RV-PAB relative to control if the iTRAQ ratio of LV-AOB, RV-AOB or LV-PAB, RV-PAB to control was greater than 2.0 and if the corresponding maximum control to control ratio was less than the LV-AOB, RV-AOB or LV-PAB, RV-PAB to control ratio. Similarly, proteins were considered underexpressed in LV-AOB, RV-AOB or LV-PAB, RV-PAB relative to control if the iTRAQ ratio of LV-AOB, RV-AOB or LV-PAB, RV-PAB to control was less than 0.5 and if the corresponding minimum control to control ratio was higher than the LV-AOB, RV-AOB or LV-PAB, RV-PAB to control ratio.
Gene ontology analysis. Gene ontology analysis was performed using "GeneGO" (http://www.genego.com/). To carry out this analysis, we used the MetaCore tool in GeneGO based on a proprietary manually curated database of human protein-protein, protein-DNA and protein compound interactions, metabolic and signaling pathways and the effects of bioactive molecules in gene expression. Each of the effected categories was provided with a P value as an indicator of the significance. The lower the P value the more significantly a category was affected. The P value was calculated by using the formula for hypergeometric distribution. In this analysis categories with P values Ͻ0.05 were considered significantly affected.
Functional and pathway enrichment analysis. GO categories in differentially expressed transcripts and proteins were identified using the Biological Processes and Molecular Functions Enrichment Analysis Database for Annotation, Visualization and Integrated Discovery (DAVID) (http://david.abcc.ncifcrf.gov/). Canonical pathway enrichment analysis was performed using Ingenuity Pathways Analysis (IPA 4.0) (http://www.ingenuity.com/). All statistics and data analysis was performed by the Beth Israel Deaconess Medical Center Genetics Core of the Genomics and Proteomics Center.
Western blot analysis. Western blot analysis was performed as previously described (31) . In brief, protein samples (25 g) were fractionated on 10% Novex Tris-Glycine gels (Invitrogen, Carlsbad, CA) and then electroblotted to nitrocellulose membranes (Invitrogen). Protein equivalency, transfer efficiency, and membrane blocking were performed as previously described (31) . Immunoblotting was per- formed by using mouse monoclonal malate dehydrogenase (MDH) and citrate synthase (CS) antibodies (1:2,000 dilution; Abcam, Cambridge, MA). Blots were detected using ECL-Plus (Amersham Pharmacia Biotech; Piscataway, NJ) with species-appropriate secondary antibodies. Densitometry analysis was performed using the ImageJ analysis software (http://rsbweb.nih.gov/ij/) (31) . Statistical analysis. Statistical analysis for infarct size, qRT-PCR, and Western blot analysis was performed using SAS (version 6.12) software package (SAS Institute, Cary, NC). The mean Ϯ SE for all data was calculated for all variables. Statistical differences between groups were evaluated by one-way ANOVA. Dunnett's test was used for comparisons between control and other groups to adjust for the multiplicity of tests.
RESULTS

Animal model of LV and RV hypertrophy.
Overall mortality in the RV-PAB and LV-AOB was 15% within the immediate postoperative period. There was no significant difference in body weight between LV-AOB versus sham-control (SC; 1.20 Ϯ 0.04 kg vs. 1.22 Ϯ 0.04 kg, respectively) or RV-PAB versus SC (1.42 Ϯ 0.06 kg vs. 1.44 Ϯ 0.07 kg, respectively). There was a significant increase in RV weight in RV-PAB versus SC-PAB (3.2 Ϯ 0.8 g vs. 1.2 Ϯ 0.3 g; 2.67-fold; P Ͻ 0.01). LV weight in LV-AOB versus SC-AOB was significantly increased (7.08 Ϯ 0.6 g vs. 4 .02 Ϯ 0.2 g; 1.76-fold; P Ͻ 0.01). Please note that all further comparisons to SC-AOB and SC-PAB will be referred to as SC unless otherwise identified. Only the ventricular free walls were used for analysis. There was no significant difference in the weight of the free wall (in grams) to body weight (in kilos) ratio between LV-AOB versus SC (1.48 Ϯ 0.14 vs. 1.5 Ϯ 0.3, respectively) or RV-PAB versus SC (1.05 Ϯ 0.31 vs. 0.98 Ϯ 0.14, respectively).
Animals were followed by weekly transthoracic echocardiography to monitor progression of LV-AOB and RV-PAB. Details about the animal models of LV and RV hypertrophy have been reported by our group in past publications (16, 25) . Fractional area change indicative of RV contractile function was 47 Ϯ 3.3% in RV-sham versus 28 Ϯ 8.3% in RV-PAB (P Ͻ 0.05). Shortening fraction as indicator for LV contractile function measured 45 Ϯ 1.7% in LV-sham versus 35 Ϯ 3.6% in LV-AOB (P Ͻ 0.05). Time points of euthanasia were selected at the end of the compensatory phase where we had previously found that considerable remodeling of the cellular and extracellular compartments had already occurred (10, 11, 13, 16) . The banding site was inspected postmortem, and the circumference of the banded portion of the descending aorta or the pulmonary artery was measured and compared with an adjacent proximal nonbanded vessel area. In each case, the banded area was confirmed to be stenotic (Ͻ50% of proximal vessel).
Microarray analysis. Microarray analysis of 3,592 nonredundant cDNAs revealed that there were 192 cDNAs commonly expressed in LV-AOB and RV-PAB with 327 cDNAs being uniquely expressed in LV-AOB and 565 cDNAs being uniquely expressed in RV-PAB (Fig. 2) . In LV-AOB there were 39 cDNAs upregulated (Ͼ1.2-fold and P Ͻ 0.05) and 280 cDNAs downregulated (Ͻ0.6 and P Ͻ 0.05) compared with LV-control. In RV-PAB there were 28 cDNAs upregulated (Ͼ1.2-fold and P Ͻ 0.05) and 378 cDNAs downregulated (Ͻ0.6 and P Ͻ 0.05) compared with RV-control.
Hierachal cluster analysis (Fig. 2) shows distinct up-and downregulated transcripts for LV-AOB versus SC and for RV-PAB versus SC.
Functional annotation clustering analysis (enrichment score Ͼ2.0, P Ͻ 0.05) is shown in Tables 1 and 2 . Functional annotation clustering analysis for LV-AOB compared with SC showed only oxidative phosphorylation a with enrichment scores greater than 2.0 (P Ͻ 0.05). RV-PAB compared with SC showed no significant clusters for upregulated cDNAs. In contrast, there were six and eight annotation clusters with enrichment scores greater than 2.0 (P Ͻ 0.05) for downregulated cDNAs in LV-AOB compared with SC and RV-PAB compared with SC, respectively (Tables 1 and 2 ).
Significant downregulated annotation clusters for LV-AOB were ribosome, protein synthesis, ATP catabolic process, cytoskeleton, response to oxidative stress, nucleotide binding, and heart and blood vessel development (Table 1 ). In RV-PAB significant annotation clusters included mitochondrion, actin and cytoskeleton protein binding, intracellular transport, sarcomere and myofibril, nuclear lumen, and oxidative phosphorylation (Table 2) .
Canonical pathway enrichment analysis revealed that only oxidative phosphorylation was common in both LV-AOB and RV-PAB (Fig. 3) . In LV-AOB-enriched pathways (ratio Ͼ0.05) included oxidative phosphorylation, mitochondria energy pathways, actin, ILK, hypoxia, calcium signaling, and pyruvate metabolism (Fig. 3) . In contrast, in RV-PAB only oxidative phosphorylation was shown to be an enriched pathway (ratio Ͼ0.05; Fig. 3 ).
Proteomic analysis: quality control analysis. Proteomic analysis identified 422 proteins in LV-AOB, and 271 proteins in RV-PAB having at least one peptide with greater than 95% confidence. The data were found to be normalized with no significant outliers. Box plot analysis showed alignment of average iTRAQ intensity values for all experimental groups (Fig. 4) . Principal component analysis indicated that in all groups the proteins expressed diverse for individual treatments, suggesting that the proteins had different expression levels in each treatment on the basis of fold change (FC Ͼ1.2) and P value (P Ͻ 0.05) (Fig. 4) .
Overall proteomic analysis. Proteomic analysis was performed to identify differentially expressed proteins. From the 1,393 proteins identified as having at least one peptide with greater than 95% confidence, there were 76 differentially expressed proteins identified as on the basis of fold change (FC Ͼ1.2) and P value (P Ͻ 0.05) within the experimental groups. There were no commonly expressed proteins identified (Fig. 4 ). There were 30 differentially expressed proteins identified as on the basis of fold change (FC Ͼ1.2) and P value (P Ͻ 0.05) in LV-AOB with 26 of these proteins identified as being uniquely expressed (Table 3) . RV-PAB had 23 differentially expressed proteins (FC Ͼ1.2; P Ͻ 0.05) identified with 19 being uniquely expressed (Table 3) .
Hierarchical cluster analysis revealed distinct protein expression patterns for all treatments compared with treatment controls in agreement with principal component analysis (Fig. 5 ). There were four commonly expressed proteins in LV-AOB and RV-PAB, myosin 2, ATP synthase subunit delta (mitochondria), heat shock protein beta 7, and stress-70 protein (mitochondria) ( Table 3) .
Functional annotation clustering (enrichment score Ͼ2.0, P Ͻ 0.001) of uniquely expressed proteins identified three annotation clusters each for LV-AOB and RV-PAB. In LV-AOB the annotation clusters identified the mitochondrion, cellular macromolecular complex assembly, and oxidative phosphorylation as being significant (P Ͻ 0.001; Table 4 ). In contrast in RV-PAB the annotation clusters identified as being significant (P Ͻ 0.001) were structural constituent of muscle, cardiac muscle tissue development, ventricular cardiac muscle morphogenesis, and circulatory system process (Table 4) .
Canonical pathway enrichment analysis is shown in Fig. 6 . In hypertrophied ventricles three enriched pathways were common to both LV-AOB and RV-PAB, namely, aldosterone signaling in epithelial cells, protein ubiquitination pathway, and pyruvate metabolism. The enriched pathway, citrate cycle, was significant (above threshold P Ͻ 0.05) in LV-AOB but not in RV-PAB (Fig. 6) . Table 5 shows oligonucleotide primers. Results were confirmed by qRT-PCR and Western blot analysis (Table 6) .
DISCUSSION
In this report we present a clinically relevant animal model of pressure-overload hypertrophy using aortic banding or pulmonary banding in growing rabbits. We present microarray and proteomic data demonstrating specific differences in transcript and protein expression levels in LV-AOB compared with RV-PAB.
Our microarray and proteomic data show distinct expression level patterns for LV-AOB, compared with RV-PAB. Our data show that in LV-AOB there is increased transcript expression A B Fig. 5 . Proteomic hierarchical cluster analysis for LV-AOB compared with LV-control (A) and RV-PAB compared with RV-control (B) to account for constitutively expressed proteins. The log fold change (lFC) in protein expression is shown with pseudocolor scale (Ϫ3 to 3) with red denoting upregulation and green denoting downregulation. The columns represent lFC from comparisons, and the rows represent the genes. Dendograms and color scale are shown at left. levels for oxidative phosphorylation, mitochondria energy pathways, actin, ILK, hypoxia, calcium, and protein kinase-A signaling and increased protein expression levels of proteins for cellular macromolecular complex assembly and oxidative phosphorylation. In contrast in RV-PAB there is increased transcript expression levels for cardiac oxidative phosphorylation and increased protein expression levels for structural constituents of muscle, cardiac muscle tissue development, and calcium handling.
The importance of increased expression levels of cardiac muscle components in RV-PAB is in agreement with our heart weight data showing that RV weight increases 2.67-fold compared with 1.76-fold in LV-AOB. The increased expression levels of cardiac muscle components would account for the differences in ventricular mass fold change required to normalize wall stress during the compensatory phase of hypertrophy. The significance of these pathways in RV-PAB could be attributed to the differences in ventricular wall thickness between RV and LV as well as the requirement of increased protein expression levels of the RV compared with LV to meet the demands of increased pressure loading.
The relative importance of the mitochondrion pathways in both LV-and RV hypertrophy is evident, in agreement with our previous observations (10, 13, 16) . Our data show that in both LV-AOB and RV-PAB expression levels for oxidative phosphorylation are enriched. The increase in these pathways would allow the LV and RV to meet the increased energy demands during the compensatory phase of hypertrophy.
In LV-AOB there was downregulation of transcripts for ribosome, protein synthesis, ATP catabolic process, cytoskeleton, response to oxidative stress, nucleotide binding, and heart and blood vessel development in agreement with previous reports demonstrating altered metabolic processes and angiogenesis (10, 11) . In contrast in RV-PAB there was downregulation of transcripts for actin and cytoskeleton protein binding, intracellular transport, and the sarcomere and myofibril. This would agree with previous reports that have suggested that in RV hypertrophy, mitochondrial and metabolic remodeling are the predominant changes in growing animals as well as in adult hypertrophy models (1, 6, 27, 32) . The downregulation of these mechanoskeletal processes occurring in the RV but not in the LV would account for the more rapid progression to contractile failure in RV-PAB compared with LV-AOB.
Our microarray data overlap in part with previous studies examining gene expression changes in RV-and LV hypertrophy. Previous studies examining RV hypertrophy due to pulmonary hypertension in the rat, with the use of a model different from ours, have reported that there was activation of proapoptotic pathways, particularly related to mitochondria and a downregulation of calcium signaling pathways (5, 17) . Kreymborg et al. (18) have compared RV and LV pressureoverload hypertrophy induced by banding of the pulmonary artery or aorta in a mouse model. These authors showed that general hypertrophy markers of muscle synthesis were significantly upregulated in both RV-PAB and LV-AOB, but there was differential expression of transcripts for extracellular matrix proteins, proteases, and their inhibitors, and developmentally regulated proteins between genes between RV-PAB and LV-AOB. However, Urashima et al. (32) have reported that transcripts for extracellular matrix components and cell adhesion were upregulated and energy pathways downregulated in RV-but not LV hypertrophy in the mouse.
Phillips et al. (29) have shown that overall protein expression levels in the normal, nondiseased rabbit LV and RV are similar. These authors suggested that the lower metabolic stress of the RV would approach that of the LV at maximal workloads and that the identical protein levels associated with energy conversion and function in the LV and RV would therefore be differentially stressed at maximal workloads.
There were four commonly expressed proteins in LV-AOB and RV-PAB. These proteins were myosin 2, ATP synthase subunit delta (mitochondria), heat shock protein ␤7, and stress-70 protein (mitochondria). Several proteomics analyses have identified alterations in metabolic proteins, heat shock proteins, and cell structure proteins as having important roles in modulating the effects of hypertrophy (19, 20) . Heat shock proteins are cardiac chaperones that increase during the development of cardiac hypertrophy. During the development of cardiac hypertrophy and heart failure, the heart accumulates misfolded proteins as a result of cellular stresses. The increase in chaperones would prevent the accumulation of misfolded proteins during the compensatory phase of hypertrophy through directed protein degradation but can become overwhelmed, leading to worsening of cardiac function. Heat shock proteins are ubiquitously expressed, and to protect cardiomyocytes from injury, heat shock proteins within the cell increase in response to externally applied stressors. In contrast with our (8) .
Despite the use of matched samples we found no overlap between transcriptomic and proteomic data using either indirect or direct comparison. This is not uncommon since previous studies have shown that the correlation between transcription and translation is not linear (26) and that little or no direct overlap is seen between transcriptomic and proteomic data in mammals (14, 22, 28) .
Foss et al. (9) showed a significantly greater overlap than expected by chance (P Ͻ 0.001) when comparing the proteomic and transcriptomic data of yeast. This showed that differentially expressed proteins were more likely to correspond to differentially expressed transcripts. However, this considerable overlap is not seen when examining data from mammals. Ghazalpour et al. (12) examined over 5,000 peptides and 22,000 transcripts of recombinant mice and found only a modest correlation between the data sets. A statistically significant correlation was found in only 21% of the genes and 15% of the proteins. Murgiano et al. (26) found no direct overlap between transcriptomic and proteomic data in pigs. 5=-GctcatGacaGcacGacaGt-3= 5=-GGGactGttGGaactGGaGa-3= MDH1 5=-catccccaaGGaGaacttca-3= 5=-GctGcacaGtcGtGacaaat-3= VDAC2 5=-cccaGtttGtttccccctat-3= 5=-GattGatccGatcctccaaa-3= IDH2 5=-tGGctcaGGtcctcaaGtct-3= 5=-ctcaGcctcaatcGtcttcc-3= ADP/ATPTL1 5=-GGcGctactttGctGGtaac-3= 5=-atGatacaGtcGcccaGacc-3= Citrate synthase 5=-ccatccacaGtGaccatGaG-3= 5=-ctttGccaacttccttctGc-3= PDHA1 5=-aacacaatGGGttcctGaGc-3= 5=-cGaGaGGacaatGGGaaaaa-3=
In conclusion our data demonstrate that enriched transcript and protein pathways differ in LV-AOB and RV-PAB during the compensatory phase of hypertrophy. In LV-AOB both transcript and protein expression levels for mitochondrial processes are enriched, indicating the importance of the mitochondrion in LV-AOB. In RV-PAB transcript levels for oxidative phosphorylation are enriched and protein levels for cardiac structural components are enriched, indicating that the mechanisms for increasing ventricular wall mass during the compensatory phase of hypertrophy are significant.
Overall these pathways suggest that the mitochondrion and related mechanisms play important but varied roles in LV-AOB and RV-PAB during the compensatory phase of hypertrophy. In LV-AOB the upregulation of oxidative phosphorylation would allow for increased energy production to meet the increased pressure demands. This would also allow for regulation of hydrogen ion accumulation and reactive oxygen species formation. The downregulation of ATP catabolic processes would further enforce these mechanisms in providing for enhanced energy demands.
In RV-PAB the upregulation of oxidative phosphorylation would as in LV-AOB allow for increased energy production to meet the demands of the increased protein expression levels for structural constituents of muscle, cardiac muscle tissue development, and calcium handling required to mediate pressureoverload hypertrophy. The enhanced calcium handling would ensure mitochondrial stability and function. In previous reports we have shown that increased cytosolic calcium accumulation destabilizes the inner mitochondrial membrane and causes the inner membrane pore to open and permit further cation movement ("futile calcium cycling"), an energy-dependent process requiring ATP to transport calcium against the electrochemical gradient out of the mitochondrion (24) . The collapse of the mitochondrial inner transmembrane potential accompanies the uncoupling of the respiratory chain. As calcium enters the mitochondria, water follows, leading to mitochondrial matrix swelling and eventually mitochondrial rupture and myocyte cell death (24) .
In RV-PAB the more rapid decline in function would most likely result from the inability of mitochondrial and calcium handling mechanisms to modulate cardiac muscle tissue demands resulting in increased hydrogen ion formation and protein degradation that overwhelms cellular regulatory mechanisms leading to more rapid worsening of cardiac function.
The identification of these divergent pathways should allow for the development of specific therapeutic intervention to allow for targeted treatment strategies in LV-AOB and RV-PAB to ameliorate morbidity and mortality. 
